drugset / Trial / NCT05830539
IN10018 Combination Therapy in Previously-treated Locally Advanced or Metastatic Solid Tumor Patients
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a multicenter, open-label, Phase Ib/II clinical trial to evaluate the safety, tolerability, and antitumor efficacy of IN10018 in combination with pegylated liposomal doxorubicin (PLD) or IN10018 in combination with PLD and anti-PD-1 in subjects with locally advanced or metastatic solid tumors who have failed or not tolerated to at least first-line system therapy.
Timeline
- Start
- 2022-03-10
- Primary completion
- 2024-08-31
- Completion
- 2024-11-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ifebemtinib | Small molecule | — | Oral |
| Subject | Toripalimab | Monoclonal antibody | 3 mg/kg | — |
| Background | Doxorubicin | Other / unclassified | 40 mg/m2 | — |
Indications
No indication recorded.